Abbott Laboratories (ABT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 112.44 |
| Open | 113.40 |
| Bid | 112.61 x 900 |
| Ask | 112.80 x 900 |
| Day's Range | 110.82 - 113.76 |
| 52 Week Range | 104.63 - 142.60 |
| Volume | |
| Avg. Volume | 5,544,459 |
| Market Cap | 198.276B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 26.29 |
| EPS (TTM) | 4.31 |
| Earnings Date | Jul 20, 2022 - Jul 25, 2022 |
| Forward Dividend & Yield | 1.88 (1.66%) |
| Ex-Dividend Date | Apr 13, 2022 |
| 1y Target Est | 140.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ABT
Related Research
- Abbott LaboratoriesAnalyst Report: Abbott LaboratoriesAbbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.RatingFair ValueEconomic Moat13 days agoMorningstar
- Bloomberg
Dangerous DIY Baby Formula Recipes Go Viral as Parents Get Desperate
(Bloomberg) -- As a nationwide baby formula shortage sends parents into crisis mode, social media posts containing dangerous misinformation about homemade formula recipes have gone viral online, racking up views in the millions. Although major networks like Facebook, TikTok and YouTube have taken steps to label photos, videos and posts with contextual information pointing to the harms of such recipes, and in some cases removed them, they have done so inconsistently, allowing the advice to contin
- Motley Fool
What Could the Baby Formula Shortage Mean for Abbott Laboratories?
With the nation's shelves looking a bit too thin on baby formula products, Abbott Laboratories (NYSE: ABT) is in the hot seat. After voluntarily starting a recall of several of its baby formulas due to dangerous contamination issues in February, a national shortage quickly developed, as the Michigan-based factory operated by the company was one of the country's major suppliers of formula. A nonstop flurry of headlines implicates Abbott Labs in a quickly escalating scandal.
- The Wall Street Journal
Why the Baby-Formula Market Is a Mess: Low Competition, High Regulation
The WIC program and regulations tamp down competition, resulting in Similac and Enfamil controlling the bulk of an inflexible, $4 billion U.S. formula market. It cracked when a major factory halted production.
